KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Current Leases (2016 - 2018)

Vertex Pharmaceuticals has reported Current Leases over the past 7 years, most recently at $9.8 million for Q4 2018.

  • Quarterly results put Current Leases at $9.8 million for Q4 2018, down 56.43% from a year ago — trailing twelve months through Dec 2018 was $9.8 million (down 56.43% YoY), and the annual figure for FY2018 was $9.8 million, down 56.43%.
  • Current Leases for Q4 2018 was $9.8 million at Vertex Pharmaceuticals, down from $11.5 million in the prior quarter.
  • Over the last five years, Current Leases for VRTX hit a ceiling of $22.5 million in Q4 2017 and a floor of $9.8 million in Q4 2018.
  • Median Current Leases over the past 5 years was $17.8 million (2014), compared with a mean of $17.1 million.
  • Biggest five-year swings in Current Leases: skyrocketed 120.71% in 2014 and later crashed 56.43% in 2018.
  • Vertex Pharmaceuticals' Current Leases stood at $17.8 million in 2014, then fell by 12.7% to $15.5 million in 2015, then grew by 24.97% to $19.4 million in 2016, then increased by 15.98% to $22.5 million in 2017, then crashed by 56.43% to $9.8 million in 2018.
  • The last three reported values for Current Leases were $9.8 million (Q4 2018), $11.5 million (Q3 2018), and $15.1 million (Q2 2018) per Business Quant data.